Recently, CDE accepted the application for the listing of Enhua Pharmaceuticals' Zosin injection, enhua Pharmaceuticals is expected to become the second domestic manufacturer after Yangzijiang to list Zosin injections. According to Minenet data, in 2016, China's public medical institutions terminal Zosin sales reached 3.81 billion yuan, ranking first in the analgesy class. In addition, Enhua Pharmaceuticals as one of the leading enterprises in the field of the central nervous system in China, relying on Mimi esters, Midazolam and other products in the domestic market leadership.
Zosin annual sales of nearly 4 billion
Zosin injection is a large variety of analgesics, terminal sales of more than 3 billion yuan. Originally developed by Wyeth-Ayerst Labs, it went on sale in the U.S. in 1990 and ceased sale in the U.S. in 2011. In October 2009, the CFDA approved the first copy of the Tyzosin injection produced by Yangzijiang Pharmaceuticals for the use of opioid analgesics to treat a variety of pain, and with its high analgesic activity, less respiratory inhibition, constipation, analgesic tolerance and addiction and other adverse reactions, the dosing rate increased rapidly. According to Minenet data, in 2016, China's public medical institutions terminals (including China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals) sales reached 3.81 billion yuan, an increase of 27.13 percent year-on-year, ranking first in the analgesic category.
, the domestic manufacturer of Zosin is only one Yangzijiang Pharmaceuticals, Nanjing Yuke in 2015 declared the production batch, but the current need for additional information. Enhua Pharmaceuticals is therefore expected to become the second manufacturer of Zosin injections after Yangzijiang. With Enhua Pharmaceuticals' sales capabilities in the field of anesthesia analgesia, it is expected to gain a market share in this large market of 4 billion levels.
Hand more than 100 million varieties
Enhua Pharmaceuticals is the only pharmaceutical company in China focused on the development and production of central nervous system drugs, its research and development area covers all central nervous system drugs, including anti-anxiety and hypnotic drugs, anti-epileptic drugs and anticonvulsant drugs, antidepressants and Anti-mania drugs, antipsychotics, opioid analgesics and their antagonists, anti-migraine drugs, general anesthetics, local anesthetics, anti-Parkinson's drugs, drugs for the treatment of degenerative diseases of the central nervous system, central excitant drugs and other drugs, is China's central nervous field drug varieties of enterprises.
According to Milnet data, in China's public medical institutions terminal, Enhua Pharmaceuticals has several products sales scale of more than 100 million yuan, including relying on mites, midazolam, lipe ketones, ziracetone and so on. In particular, relying on Mimi esters, Mida Zolun as the company's core first-line varieties, its market share has been maintained at a high level for a long time, benefiting from industry growth and the company's product advantage, the company's first-line varieties are expected to continue to maintain stable growth in the next few years.
Relying on Mist is a new type of anesthetic, suitable for general anaesthetic induction, with cyclical stability, no inhibitory effect and other advantages, high safety, the original research manufacturer is Johnson and Johnson Group, in 1981 Johnson and Johnson abandoned the product, in 1986 relying on Mist emulsion was born. At present, the domestic production enterprises rely on Mimi esters, import 1, domestic 2. Enhua Pharmaceuticals produces relying on Mimi esters in China's public medical institutions terminal market share of more than 90%, firmly occupy the first position in the market.
, mainly used for pre-anaesthetic administration, general anaesthetic induction and maintenance, ICU patient sedative. According to Minenet data, in 2016, the public medical institutions terminal, Enhua Pharmaceuticals production of Mida Zolun sales of up to 290 million yuan, an increase of 26.09 percent year-on-year, market share of up to 79.01 percent.
In addition, Enhua Pharmaceuticals' growth varieties include right metoxifen and propofol, both of which have a large market capacity, although with a small market share, and the potential variety, riffentanil, which will bring in 100 million to 200 million yuan in revenue over two years with the help of the company's anaesthetic sales platform, which was launched in 2014.
Steady growth in performance
The latest data show that Enhua Pharmaceuticals achieved operating income of RMB2,519 million in the first three quarters of 2017, up 11.32% YoY;
the central nervous system drug sub-sector market space is broad, the domestic central nervous system drug use compared to developed countries are still in the initial stage, so the development of space potential is huge. In addition, due to strict government control, high barriers to entry, Enhua Pharmaceuticals as a domestic central nervous field of the full layout of the scarce enterprises, for many years focused on the field of deep-ploughing the central nervous system, has built a strong moat; (Mi Net)